# A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery

> **NCT07182682** · PHASE3 · RECRUITING · sponsor: **Dizal (Jiangsu) Pharmaceutical Co., Ltd.** · enrollment: 360 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** sunvozertinib
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT07182682
- **Lead sponsor:** Dizal (Jiangsu) Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2029-09
- **Final completion:** 2031-01
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07182682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07182682, "A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT07182682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*